In a meta-analysis of 25 trials of antihy- pertensive therapy for patients with prevalent CVD (including stroke) but without hypertension, patients receiving antihyper- tensive medications had a pooled RR for stroke of 0.77 (95% CI, 0.61 0.98) compared with control subjects.232 The magni- tude of the RR reduction was greater for stroke than for most other cardiovascular outcomes, although the absolute risk reductions were greater for other outcomes because of their greater relative frequency. In a separate meta-analysis of 13 trials involving 80594 individuals, among those either with prevalent atherosclerotic disease or at high risk for developing it, angiotensin-convert- ing enzyme (ACE) inhibitors (ACEIs) or angiotensin receptor blocker (ARB) therapy reduced the risk of a composite primary outcome including stroke by 11%, without variability by base- There was also a significant reduction in fatal and nonfatal strokes (OR, 0.91; 95% CI, 0.86 0.97). Non ACEI/ ARB therapies were allowed, but meta-regression analyses provided evidence that the benefits were not due solely to BP reductions during the trial. 